One of the most important prerequisites of the successful implementation of pharmacogenomics into the clinic is the increase of the general public’s awareness over the benefits of pharmacogenomics in rationalizing drug use.
Recognizing this fact, the Golden Helix Foundation organizes in Rome, Italy the 2nd U-PGx Personalized Medicine Public Day. The theme of the meeting will be “La Farmacogenomica della Medicina di Precisione il Progetto Europeo “Ubiquitous Pharmacogenomics” and will be organized at the Fleming Auditorium of the Università degli Studi di Roma “Tor Vergata” in the afternoon of January 21st, 2019 (15:00 – 18:00 p.m.) and is part of the dissemination and outreaching activities of the Ubiquitous Pharmacogenomics (UPGx) project, funded by the European Commission (H2020-668353).
This event is meant for the general public, patient organisations, regulators, insurers and policy makers.
Registration is FREE-OF-CHARGE. During the break, drinks and food will be served for free.
On behalf of the Organizing Committee
Co-organized by: |
Funded by:
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 668353. |
Under the auspices of:
Introduction
About U-PGX
Speakers
Scientific Program
Registration
Gallery
Videos
One of the most important prerequisites of the successful implementation of pharmacogenomics into the clinic is the increase of the general public’s awareness over the benefits of pharmacogenomics in rationalizing drug use.
Recognizing this fact, the Golden Helix Foundation organizes in Rome, Italy the 2nd U-PGx Personalized Medicine Public Day. The theme of the meeting will be “La Farmacogenomica della Medicina di Precisione il Progetto Europeo “Ubiquitous Pharmacogenomics” and will be organized at the Fleming Auditorium of the Università degli Studi di Roma “Tor Vergata” in the afternoon of January 21st, 2019 (15:00 – 18:00 p.m.) and is part of the dissemination and outreaching activities of the Ubiquitous Pharmacogenomics (UPGx) project, funded by the European Commission (H2020-668353).
This event is meant for the general public, patient organisations, regulators, insurers and policy makers.
Registration is FREE-OF-CHARGE. During the break, drinks and food will be served for free.
On behalf of the Organizing Committee
Co-organized by: | Funded by: This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 668353. |
Under the auspices of:
Clinical application of pharmacogenomics knowledge will result in less ‘trial and error’ prescribing and more efficacious, safer and cost-effective drug therapy. However, despite the major advances in pharmacogenomics and several commercially available pharmacogenomics tests, its application in routine patient care remains very limited. The U-PGx consortium will address major challenges and obstacles for implementation of pharmacogenomics testing in patient care, taking into account the diversity of healthcare systems and citizens across Europe. Specifically, U-PGx will investigate if the emerging approach of pre-emptive genotyping of an entire panel of important pharmacogenomics markers is cost-effective and results in a better outcome for patients. With the pre-emptive pharmacogenomics testing approach data on multiple important pharmacogenes are collected prospectively and embedded into the patients’ electronic record. Typically, it alerts prescribers and pharmacists through electronic clinical decision support systems when a drug is ordered or dispensed for a patient with an at-risk genotype. The new model of personalised medicine through pre-emptive pharmacogenomics testing will be conducted at a large scale in seven existing European health care environments in the Netherlands, Spain, UK, Italy, Austria, Greece, and Slovenia.
Invited Speakers
Moderator:
Giuseppe Novelli, Rome, Italy
Speakers:
Paola Borgiani, Rome, Italy
Erika Cecchin, Aviano, Italy
Emilio Di Maria, Genova, Italy
Federico Innocenti, Chapel Hill, NC, USA
Antonio Messina, Rome, Italy
Walter Ricciardi, Rome, Italy
Domenica Taruscio, Rome, Italy
Giuseppe Toffoli, Aviano, Italy
Scientific Program
(Lectures will be delivered in Italian)
15:00 Apertura lavori
Giuseppe Novelli, Rettore dell’ Università di Roma “Tor Vergata”, Professore di Genetica Medica
Contributi:
Paola Borgiani, Professore di Genetica Medica, Università di Roma “Tor Vergata”
Farmacogenetica/Farmacogenomica: di cosa si tratta? Dalla ricerca alla pratica clinica
Emilio Di Maria, Professore di Genetica Medica, Università di of Genova; Coordinatore del Gruppo di lavoro di Farmacogenetica della Società Italiana di Genetica Umana
Applicazioni cliniche della Farmacogenetica/Farmacogenomica: dalla valutazione allo sviluppo di percorsi appropriati
Erika Cecchin, Dirigente Farmacista, Unità Operativa di Farmacologia Sperimentale e Clinica, Centro di Riferimento Oncologico, IRCCS Aviano
Il Progetto Europeo U-PGx: rendere accessibile ad ogni cittadino europeo una terapia farmacologica personalizzata
Federico Innocenti, Associate Professor; Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill; Co-Director, Center for Pharmacogenomics and Individualized Therapy, Chapel Hill, NC, USA
Genomica applicata alla terapia del cancro
Walter Ricciardi, President, World Federation of Public Health Association (WFPHA)
Salute pubblica di precisione: sfide, fatti e promesse
Domenica Taruscio, Istituto Superiore di Sanità, Direttore del centro Nazionale malattie
U-PGx e malattie rare
Giuseppe Toffoli, Direttore, SOC Farmacologia Sperimentale e Clinica – CRO National Cancer Institute; Principal Investigator; WP 4G “Ubiquitous Pharmacogenomics (U-PGx)
Farmacogenetica/Farmacogenomica: Aspetti regolatori e policy
Antonio Messina, Managing Director,Merck Serono spa, Rome, Italy
Pharma 4.0 il ruolo dei biomarcatori nell’innovazione
Saluti di Monsignor Andrea Lonardo, Vicariato Diocesi di Roma, Ufficio per la pastorale della cultura et dell’università
17:15 Discussione
18:00 Chiusura lavori
Registration
Registration for this meeting is closed.